Jouleferon Articles

Novartis drops development of albinterferon and Mycograb in candidiases, taking $590 million charge

6 October 2010

Human Genome Sciences sees little hope of FDA approval for hep C drug Zalbin in bi-monthly regimen

15 June 2010

Human Genome shares drop as partner Novartis withdraws European MAA for Jouleferon/Zalbin for hep C; and Gilead drops Ph II hep C drug

20 April 2010

Showing 1-3 of 3 articles

Go to beginningPrevious
  • 1
NextGo to end